Loading
Antibodies, Neutralizing / COVID-19 Vaccines / Immunogenicity, Vaccine · Journal article
Human Vaccines & Immunotherapeutics · August 4, 2026
Encouraging direction, but not yet definitive.
This comparative immunogenicity study found that mRNA-1273 and BNT162b2 bivalent boosters elicit comparable anti-spike IgG levels and neutralizing antibody titers in nursing home residents against both ancestral and Omicron BA.4/5 strains. The findings support vaccine interchangeability based on humoral immunity, but rely on serologic surrogates rather than clinical protection endpoints.
Comparative longitudinal immunologic study. U.S. nursing home residents who received either mRNA-1273 or BNT162b2 bivalent booster vaccines. Intervention: mRNA-1273 (Spikevax, Moderna) bivalent booster vaccine. Compared with: BNT162b2 (Comirnaty, Pfizer-BioNTech) bivalent booster vaccine. United States.
Spike-binding antibody levels were comparable between mRNA-1273 and BNT162b2 vaccine formulations Neutralization titers were comparable between mRNA-1273 and BNT162b2 vaccine formulations Both vaccine groups demonstrated strong humoral responses to ancestral Wuhan strain and Omicron BA.4/5 subvariants
No clinical outcomes (infection, hospitalization, mortality) measured
Clinicians may use either mRNA-1273 or BNT162b2 bivalent boosters interchangeably in nursing home residents without expecting differential serologic responses. However, this equivalence is based on antibody levels and does not directly predict clinical protection against infection or severe disease.
A sound comparative immunogenicity study in a vulnerable population showing equivalent responses between two widely used vaccines, but limited by cross-sectional design, surrogate endpoints, and lack of clinical outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians may use either mRNA-1273 or BNT162b2 bivalent boosters interchangeably in nursing home residents without expecting differential serologic responses. However, this equivalence is based on antibody levels and does not directly predict clinical protection against infection or severe disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Nursing home residents (NHRs) remain among the most vulnerable to severe outcomes from SARS-CoV-2 infection. While mRNA-1273 (Spikevax, Moderna) and BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccines are widely used in this population, comparative data on their immunogenicity, particularly after bivalent boosters, remain limited. We conducted a longitudinal immunologic evaluation of U.S. NHRs who received either the mRNA-1273 or BNT162b2 bivalent vaccine. Serum samples were collected 10-30 d post-vaccination. Anti-spike IgG levels were measured using a Luminex bead-based assay, and neutralizing titers were assessed via pseudovirus neutralization. Comparative analyses of the titer distributions were performed using two-sided Wilcoxon rank-sum tests. Both vaccine groups demonstrated strong humoral responses to the ancestral Wuhan strain and Omicron BA.4/5 subvariants. Spike-binding antibody levels and neutralization titers were comparable between the mRNA -1273 and BNT162b2 vaccine formulations. Conclusions: Both mRNA-1273 and BNT162b2 mRNA vaccines elicit similarly robust humoral immunity in NHRs, supporting their interchangeable use in booster strategies. Our findings underscore the importance of timely booster administration over exact product selection in protecting this high-risk, immunosenescent population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.